Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
出版年份 2018 全文链接
标题
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
作者
关键词
BCR-ABL1, Tyrosine kinase, Tyrosine kinase inhibitors, Resistance
出版物
Molecular Cancer
Volume 17, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-02-15
DOI
10.1186/s12943-018-0780-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia
- (2017) S H Han et al. LEUKEMIA
- Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis
- (2017) J A Cutler et al. LEUKEMIA
- Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
- (2017) S Reckel et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure
- (2017) Jorge Cortes et al. Journal of the National Comprehensive Cancer Network
- Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
- (2016) TaeHyung Kim et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
- (2016) Isabel Ben-Batalla et al. CLINICAL CANCER RESEARCH
- Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface
- (2016) John Wojcik et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib
- (2016) Dongmei Wang et al. LEUKEMIA & LYMPHOMA
- Natural course and biology of CML
- (2015) Bradley Chereda et al. ANNALS OF HEMATOLOGY
- shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance
- (2015) J. S. Khorashad et al. BLOOD
- Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
- (2015) M. W. Deininger et al. BLOOD
- Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
- (2015) Simona Soverini et al. Clinical Lymphoma Myeloma & Leukemia
- β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) A M Eiring et al. LEUKEMIA
- Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy
- (2014) Cristian Ferri et al. BLOOD CELLS MOLECULES AND DISEASES
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia
- (2014) Alessandro Morotti et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
- (2014) L. Noens et al. HAEMATOLOGICA
- Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
- (2014) A M Eiring et al. LEUKEMIA
- Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
- (2014) M Schmidt et al. LEUKEMIA
- The Capable ABL: What Is Its Biological Function?
- (2014) J. Y. J. Wang MOLECULAR AND CELLULAR BIOLOGY
- Incidence of bcr-abl fusion transcripts in healthy individuals
- (2014) SAID I. ISMAIL et al. Molecular Medicine Reports
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
- (2014) Liran I. Shlush et al. NATURE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
- (2014) Q Zheng et al. PHARMACOGENOMICS JOURNAL
- Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy
- (2014) Don L. Gibbons et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
- (2013) S. Soverini et al. BLOOD
- Analysis of BCR/ABL transcripts in healthy individuals
- (2013) J.A. Boquett et al. GENETICS AND MOLECULAR RESEARCH
- Structure and Dynamic Regulation of Abl Kinases
- (2013) Shoghag Panjarian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia
- (2013) Samantha B. Foley et al. Cell Reports
- Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) M. Baccarani et al. ANNALS OF ONCOLOGY
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
- (2012) F Efficace et al. BRITISH JOURNAL OF CANCER
- Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
- (2012) S. Angelini et al. HAEMATOLOGICA
- Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis
- (2012) Simona Soverini et al. PHARMACOGENOMICS
- Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia
- (2011) Prasanth Ganesan et al. AMERICAN JOURNAL OF HEMATOLOGY
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
- (2011) Florian Grebien et al. CELL
- Common Leukemia- and Lymphoma-Associated Genetic Aberrations in Healthy Individuals
- (2011) Jianbo Song et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?
- (2011) S. Soverini et al. ONCOLOGIST
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
- (2008) S. Dulucq et al. BLOOD
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- Imatinib mesylate for the treatment of chronic myeloid leukemia
- (2008) Simona Soverini et al. Expert Review of Anticancer Therapy
- Mathematical Models of Cancer Stem Cells
- (2008) Franziska Michor JOURNAL OF CLINICAL ONCOLOGY
- Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
- (2008) Ji Wu et al. JNCI-Journal of the National Cancer Institute
- Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- (2008) L L Remsing Rix et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started